Document is current

Article History

Received: 23 August 2025

Accepted: 12 March 2026

First Online: 9 May 2026

Declarations

:

: TN: Clinical trial support to the institution by Novartis, Clinical trial support (drug only supply) to the institution by Karyopharm, Consultant to Alexion. JEL: Consultancy: Dedham Group, Jasper Therapeutics, Astellas, Dava Oncology, Novartis, Agios/Servio, Boxer Capital, Jazz, BerGenBio, Millenium Pharma/ Takeda, ElevateBio Management, Daiichi Sankyo, AbbVie, Servier; Research Funding: Syntrix Pharmaceuticals, Celgene/ Bristol Myers Squibb.AK: Research Support: Protagonist, Blueprint Medicines Corporation, GSK - Sierra Oncology, Prelude Pharmaceuticals, Bristol Myers Squibb, Morphosys; Consultancy: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, PharmaEssentia, CTI Biopharma; Honoraria: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, PharmaEssentia, CTI Biopharma; Speakers Bureau: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, PharmaEssentia, CTI Biopharma. RK: Consultancy/honoraria: Servier, Geron, Bristol Myers Squibb , Sbio, PharmaEssentia, Rigel Speakers Bureau: Servier, Sbio , Pharma Essentia, RigelDHL: Consultant fee from Lexicon PharmaceuticalsThe remaining authors decare that they have no competing interests to disclose.